论文部分内容阅读
目的研究分析甲胎蛋白对PTEN活性产生抑制引起肝癌细胞耐受ATRA发生凋亡。方法选取2012年11月~2013年11月期间本院诊治36例肝癌患者,将患者术后肝癌细胞制成标本。结果人体肝癌HepG2与Bel 7402细胞均存在PTEN表达,经160μmol/L的ATRA处理24 h后可加强这些细胞的PTEN的表达。Co-IP技术实验得知甲胎蛋白可与PTEN相结合,最终对ATRA产生影响。结论肝癌细胞中表达的甲胎蛋白可与PTEN相结合,最终发现AFP为肝癌细胞耐受ATRA的重要因子。
Aim To study whether AFP inhibits the activity of PTEN and induces ATRA cell apoptosis in hepatoma cells. Methods From November 2012 to November 2013, 36 patients with HCC were diagnosed and treated in our hospital, and the specimens of patients with postoperative liver cancer were selected. Results The expression of PTEN was found in HepG2 and Bel 7402 cells, and the expression of PTEN in these cells was enhanced by treatment with 160 μmol / L ATRA for 24 h. Co-IP technology experiments that AFP can be combined with PTEN, the final impact on ATRA. CONCLUSION: Alpha-fetoprotein expressed in hepatocellular carcinoma cells can be combined with PTEN. Finally, AFP is found to be an important factor for ATRA tolerance of hepatoma cells.